In this multicenter, randomized, open-label pilot study, investigator aims to recruit 140 patients with LVO strokes in the terminal internal carotid artery (ICA) or proximal middle cerebral artery (MCA) who were eligible for EVT with a last-known-well (LKW) to puncture ≤ 12 hours. Patients will be randomized in a 1:1 ratio to semaglutide or standard therapy. Patients in the semaglutide group will receive the medication on the day of (D0) and 1 week (D7) after EVT. Interval imaging and blood tests will be arranged to ascertain the degree of BBB leakage, final infarct size, inflammation and gene expression pre and post treatment. Investigator shall recruit 40 patients from the Prince of Wales Hospital and 100 patients from Linyi People's Hospital.
Detailed study procedures are as follows:-
1. LVO stroke patients will have received CTA and perfusion prior to screening.
2. Informed consent from patient or next of kin will be obtained for eligible patients.
3. After informed consent, patient will be randomized into semaglutide or standard treatment in a 1:1 ratio by computer-generated codes.
4. Patients randomized into the semaglutide group will receive 0.5mg subcutaneous injection of the drug before or during EVT, and 7 days after the procedure. i.e. semaglutide group will receive a total of 2 injections.
5. All study subjects will receive plain CT brain and perfusion D4-7 post EVT to look for MBE, sICH and hyperperfusion. Additional brain imaging may also be arranged as per clinical needs.
6. All study subjects will receive a standardized stroke protocol MRI D14-21 after EVT for quantification of infarct volume.
7. NIHSS before and immediately after, D3, D14-21, D90±7 post-EVT will be assessed.
8. mRS before, D14-21, D90±7 post-EVT will be assessed.
9. Blood test before and immediately, 3 days and 14 days after EVT (D0pre, D0post, D3, D14-21) will be collected for neurovascular inflammatory markers and transcriptomic analysis.
10. Capillary blood glucose, blood pressure and pulse will be measured four times daily in accordance to the standardized post-EVT protocol during the first 5 days hospitalization. The frequency of monitoring may increase according to the clinical needs.
11. The following data will be collected:
1. Demographic data: date of birth, date of death (if applicable), smoking and drinking status
2. Medical comorbidities: Hypertension, diabetes mellitus, hyperlipidemia, congestive heart failure, atrial fibrillation, ischemic heart disease, history of ischemic or hemorrhagic stroke, etc.
3. Co-medications: Anticoagulants (apixaban, dabigatran, edoxaban, rivaroxaban, heparin, warfarin), antiplatelet agents (aspirin, clopidogrel, ticagrelor, cilostazol), lipid-lowering agents (simvastatin, atorvastatin, rosuvastatin, pravastatin, fluvastatin, ezetimibe, gemfibrozil, fenofibrate, erenumab), antihypertensive (angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta blockers, calcium channel blockers, diuretics, aldosterone antagonists, nitrates, etc.), non-steroidal antiinflammatory agents or cyclo-oxygenase2 inhibitors (indomethacin, ibuprofen, diclofenac, celecoxib, etorixocib), glucose lowering drugs (metformin, gliclazide, glimepiride, empagliflozin, dapagliflozin, insulin).
4. Routine blood tests including hemoglobin, white cell count, lymphocyte count, neutrophil count, creatinine, alanine transferase, alkaline phosphatase, bilirubin, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, total cholesterol, triglyceride, fasting glucose, glycated hemoglobin A1c, etc. These blood tests are part of routine clinical care pre- and post-stroke.
5. Imaging data: ASPECT score, site of occlusion, collateral score, volume of infarct core, penumbra, mismatch volume and mismatch ratio.
6. Stroke time metrics: LKW-to-hospital, -imaging, -needle, -puncture, -reperfusion time.
7. EVT outcomes: modified thrombolysis in cerebral infarction (TICI) score.
8. Occurrence of MBE, asymptomatic or symptomatic ICH, hemorrhagic transformation, subarachnoid hemorrhage (see Endpoint measurement for details).
